Get the Stockscreener App
63.83
1.27%
-0.82
After Hours:
63.97
0.14
+0.22%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $63.83, with a volume of 7.53M.
It is down -1.27% in the last 24 hours and up +12.08% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$64.65
Open:
$64.13
24h Volume:
7.53M
Relative Volume:
0.63
Market Cap:
$130.39B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.92
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-1.38%
1M Performance:
+12.08%
6M Performance:
+5.09%
1Y Performance:
+33.51%
1-Day Range:
$63.35
$64.33
1-Week Range:
$63.00
$65.25
52-Week Range:
$42.52
$68.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
63.83 | 130.12B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,180.16 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.35 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.46 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.84 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.88 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma - medcitynews.com
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Can BMY's First CELMoD Approval Support Its Growth Strategy? - TradingView
USFDA Clears Bristol Myers Squibb's Zenbexus Combo for Rare Blood Cancer - Medical Dialogues
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment - Benzinga
Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore - AD HOC NEWS
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - finance.yahoo.com
Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS (iberdomide), its first CELMoD, in multiple myeloma - Dealroom
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - AOL.com
Bristol-Myers Can't Duck UMB Suit Targeting Drug Approvals - Law360
WRIGHT INVESTORS SERVICE INC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma - Investing.com
US FDA approves Bristol Myers' blood cancer treatment - Reuters
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma By Investing.com - Investing.com UK
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse - bastillepost.com
ZENBEXUS becomes first FDA-approved CELMoD for myeloma - Stock Titan
Bristol-Myers Squibb Sued Over Heart Disease Treatment Patent - news.bloomberglaw.com
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Lawsuit against Bristol Myers over delayed cancer drug is revived By Reuters - Investing.com
Bristol-Myers Must Resume Court Fight on Drug Approval Diligence - news.bloomberglaw.com
Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is RevivedU.S. News - U.S. News - Money
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com UK
IMS Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’ - Benzinga
Bristol Myers Squibb stock holds near recent highs as AI drug discovery pact and Houston build-out r - AD HOC NEWS
US FDA approves Bristol Myers' blood cancer treatment | Business Information & News | FE - Westlaw Today
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory - ABC13 Houston
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? - TradingView
Why Bristol Myers Squibb (BMY) Is Back In The Spotlight - simplywall.st
AstraZeneca focuses on future as BMS merger talk dismissed - Business Weekly
Handelsbanken Fonder AB Sells 446,938 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Assenagon Asset Management S.A. Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
How AstraZeneca’s $400bn deal unravelled - Financial Times
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb to build $2.3B advanced manufacturing plant in Houston, creating 500 jobs - Waco Tribune-Herald
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Stock News Today - TradingKey
BMS banks on Texas for $2.3bn multi-modal manufacturing facility - Pharmaceutical Technology
AstraZeneca's Failed $400 Billion Merger Talks with Bristol Myers Squibb - GuruFocus
Unique Wealth Strategies, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
News | Bristol Myers Squibb plans $2.3 billion Houston campus - CoStar
Bristol Myers Commits $2.3 Billion to Flexible Houston Drug Campus - TechStock²
Bristol Myers Squibb Unveils $2.3B Houston Life Science Project - CommercialSearch
Pharmaceutical giant to build $2.3B plant, create 500 jobs in Texas - USA Today
Bristol Myers Squibb picks Houston for $2.3B drug manufacturing campus - cw39.com
Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus - InnovationMap
Bristol Myers Squibb to Build $2.3 Billion Multi-Modal Manufacturing Campus in Houston - BioPharm International
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bristol Myers Squibb Co Stock (BMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops |
Apr 01 '26 |
Option Exercise |
0.00 |
3,307 |
0 |
27,580 |
| Elkins David V | EVP, Chief Financial Officer |
Apr 01 '26 |
Sale |
61.67 |
30,000 |
1,850,016 |
159,248 |
0.04%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):